Wang Yun-feng, Yang Hui-xia
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Fu Chan Ke Za Zhi. 2007 Mar;42(3):157-60.
To investigate the incidence, treatment and pregnant outcomes of women with hypothyroidism during pregnancy.
A retrospective analysis was conducted on the perinatal care, treatment and pregnant outcomes of 31 pregnant women with hypothyroidism from Jan.1995 to May.2006 in our hospital. All subjects were received in the high risk clinic, and the thyroid function was monitored every 1.0 - 1.5 months. The dosage of LT4 was adjusted to maintain the normal level of thyroid function.
The incidence of maternal hypothyroidism during the study period was 1.27 per thousand (31/24 327) [0.19 per thousand (1/5251) - 2.32 per thousand (15/6456)]. The average LT4 dosage in pre-gestation, the first, second, third trimester and postpartum was (33 +/- 35), (51 +/- 36), (68 +/- 42), (76 +/- 42) and (38 +/- 34) microg/d, respectively. Compared with the pre-gestational period, the dosage in the first trimester or postpartum was higher although the difference was not significant (P>0.05). The required dose of LT4 during the second and third trimester was respectively, remarkably increased compared to pre-gestational period (P<0.05). The average increase of the dose of LT4 required during the pregnancies was about 35%. All of 31 women had uneventful pregnancies. No perinatal mortality or congenital hypothyroidism occurred. The incidence of abnormal glucose metabolism was up to 16.1%.
The incidence of maternal hypothyroidism is increasing yearly. It is of great value in improving the pregnant outcome through adjusting the LT4 dose during pregnancy and close monitoring of maternal and fetal status.
探讨妊娠期甲状腺功能减退症妇女的发病率、治疗及妊娠结局。
对1995年1月至2006年5月我院收治的31例妊娠期甲状腺功能减退症孕妇的围产期保健、治疗及妊娠结局进行回顾性分析。所有研究对象均在高危门诊就诊,每1.0 - 1.5个月监测一次甲状腺功能。调整左甲状腺素(LT4)剂量以维持甲状腺功能正常水平。
研究期间孕产妇甲状腺功能减退症的发病率为千分之1.27(31/24327)[千分之0.19(1/5251) - 千分之2.32(15/6456)]。妊娠前、妊娠第一、第二、第三孕期及产后LT4的平均剂量分别为(33±35)、(51±36)、(68±42)、(76±42)和(38±34)μg/d。与妊娠前期相比,妊娠第一期或产后的剂量较高,尽管差异无统计学意义(P>0.05)。妊娠第二和第三孕期所需的LT4剂量与妊娠前期相比显著增加(P<0.05)。妊娠期所需LT4剂量平均增加约35%。31例妇女均妊娠顺利。未发生围产儿死亡或先天性甲状腺功能减退症。糖代谢异常的发生率高达16.1%。
孕产妇甲状腺功能减退症的发病率逐年上升。通过孕期调整LT4剂量并密切监测母婴状况对改善妊娠结局具有重要价值。